ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0356

PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis

Pamela F. Weiss1, Timothy G. Brandon2, Amita Aggarwal3, RUBEN BURGOS-VARGAS4, Robert Colbert5, Gerd Horneff6, Rik Joos7, Ronald Laxer8, Kirsten Minden9, Angelo Ravelli10, Nicolino Ruperto11, Judith Smith12, Matthew Stoll13, Shirley Tse8, Filip Van den Bosch14, Walter P. Maksymowych15, Robert Lambert16, David Biko2, Nancy A. Chauvin17, Michael L. Francavilla18, Jacob Jaremko15, Nele Herregods19, Ozgur Kasapcopur20, Mehmet YILDIZ21, Hemalatha Srinivasalu22, Ray Naden23 and Alison Hendry24, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 4Hospital General de Mexico, Ciudad de México, Mexico, 5NIH/NIAMS, Bethesda, MD, 6Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, 7Ghent University, Basel, Switzerland, 8The Hospital for Sick Children, Toronto, ON, Canada, 9Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, 10Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy, 11IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 12University of Wisconsin, Madison, WI, 13University of Alabama at Birmingham, Birmingham, AL, 14Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 15University of Alberta, Edmonton, AB, Canada, 16Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 17The Cleveland Clinic, Hummelstown, PA, 18University of South Alabama College of Medicine, Mobile, AL, 19Ghent University Hospital, Ghent, Belgium, 20Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, 21Istanbul University-Cerrahpasa Department of Pediatric Rheumatology, Istanbul, Turkey, 22Children's National Hospital, Washington, DC, 23Auckland City Hospital, Auckland, New Zealand, 24Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand

Meeting: ACR Convergence 2023

Keywords: classification criteria, Pediatric rheumatology, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are not validated and refinement may be necessary for optimal performance. We aimed to investigate differences amongst youth with clinically diagnosed juvenile SpA who met axJSpA classification criteria who did and did not fulfill the PRINTO provisional enthesitis/spondylitis-related criteria.

Methods: This was a retrospective cross-sectional sample of international youth who had juvenile SpA ascertained by the treating physician. All youth had onset of symptoms prior to age 18 and fulfilled the recently validated axJSpA classification criteria. The axJSpA classification criteria consist of 7 domains: imaging – active inflammation, imaging – structural lesions, pain chronicity, pain pattern, pain location, stiffness, and genetics/family history. A youth with juvenile SpA is classified as having axial disease with a cumulative score of ≥55 (out of 100). To meet the PRINTO criteria for enthesitis/spondylitis-related arthritis youth must fulfill one of 3 major criteria (Table 1). Data were abstracted from subjects’ medical records. All MRI scans underwent central imaging review by at least 2 central raters. Patient demographics, clinical manifestations, and physician and patient-reported outcomes were evaluated using standard descriptive statistics. Differences between groups were compared using Wilcoxon signed-rank test or chi-square as appropriate.

Results: Of 143 patients that met axJSpA criteria, 100 (69%) fulfilled the PRINTO provisional criteria for enthesitis/spondylitis-related arthritis. Thirty-four (23%) did not fulfill any of the 3 major PRINTO criteria due to lack of peripheral disease manifestations. The frequency with which each major and minor criteria were fulfilled is listed in Table 1. Demographics, family history of SpA, location of back pain, and duration of pain were not statistically different between those who did and did not meet PRINTO criteria (Table 2). Those who fulfilled the PRINTO criteria had significantly more morning stiffness lasting ≥15 minutes (p=0.02), peripheral arthritis (p< 0.01), enthesitis (p< 0.01), and HLA-B27 positivity (p=0.02). Patients who did not meet the PRINTO criteria had a significantly higher percentage of pain duration ≥12 weeks (p=0.01). There were no significant differences in the prevalence of inflammatory or structural lesions on MRI between the two groups (Table 3).

Conclusion: A third of children classified with axJSpA remain unclassifiable by the provisional PRINTO enthesitis/spondylitis-related criteria. The clinical and imaging manifestations of axial disease were not significantly different between those who did and did not fulfill the provisional PRINTO criteria. The phenotypic differences between those who were and were not classified by the provisional PRINTO criteria are confined to peripheral disease manifestations. Modification of the second major criterion of the PRINTO provisional criteria may facilitate capture of youth with primarily axial disease.

Supporting image 1

Supporting image 2

Supporting image 3

Legend. ^Unequivocal evidence of inflammatory lesions typical of axial disease: bone marrow edema in ≥3 SI joint quadrants across all SI joint MRI slices. #Unequivocal evidence of structural lesion(s) typical of axial disease: erosion in ≥3 quadrants or sclerosis or fat lesion in ≥2 SI joint quadrants or backfill or ankylosis in ≥2 joint halves across all SI joint MRI slices.


Disclosures: P. Weiss: Eli Lilly, 2, Novartis, 2, Pfizer, 2; T. Brandon: None; A. Aggarwal: None; R. BURGOS-VARGAS: None; R. Colbert: None; G. Horneff: GSK, 6, Janssen, 6, MSD, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 6, Sobi, 6; R. Joos: None; R. Laxer: None; K. Minden: Amgen, 6, Medac, 6, Novartis, 6, Pfizer, 6; A. Ravelli: AbbVie/Abbott, 12, honoraria for consultancies or speaker bureaus from, Novartis, 12, honoraria for consultancies or speaker bureaus from, Pfizer, 12, honoraria for consultancies or speaker bureaus from; N. Ruperto: Ablynx, 2, 6, AstraZeneca-Medimmune, 2, 6, Bayer, 2, 6, Biogen, 2, 6, Boehringer-Ingelheim, 2, 6, Bristol-Myers Squibb (BMS), 2, 5, 6, Celgene, 5, 12, Personal Fees, Non-Financial Support, Eli Lilly, 2, 5, 6, EMD Serono, 2, 6, F. Hoffman-La Roche, 2, 5, 6, GlaxoSmithKlein (GSK), 2, 5, 6, Janssen, 2, 5, 6, Merck/MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, R-Pharma, 2, 6, Sinergie, 2, 6, Sobi, 2, 5, 6, UCB, 2, 5; J. Smith: None; M. Stoll: Novartis, 2; S. Tse: None; F. Van den Bosch: AbbVie, 2, 6, Amgen, 2, BMS, 6, Celgene, 6, Eli Lilly, 2, Galapagos, 2, Janssen, 2, 6, Merck, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB Pharma, 2, 6; W. Maksymowych: AbbVie, 2, 5, 6, BMS, 2, 6, Boehringer-Ingelheim, 2, CARE Arthritis Ltd, 4, CARE Arthritis Ltd., 4, Celgene, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, Janssen, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; R. Lambert: Calyx, 2, CARE Arthritis Limited, 2, Image Analysis Group, 2; D. Biko: None; N. Chauvin: None; M. Francavilla: None; J. Jaremko: None; N. Herregods: None; O. Kasapcopur: Novartis, 6, Pfizer, 6; M. YILDIZ: None; H. Srinivasalu: None; R. Naden: None; A. Hendry: None.

To cite this abstract in AMA style:

Weiss P, Brandon T, Aggarwal A, BURGOS-VARGAS R, Colbert R, Horneff G, Joos R, Laxer R, Minden K, Ravelli A, Ruperto N, Smith J, Stoll M, Tse S, Van den Bosch F, Maksymowych W, Lambert R, Biko D, Chauvin N, Francavilla M, Jaremko J, Herregods N, Kasapcopur O, YILDIZ M, Srinivasalu H, Naden R, Hendry A. PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/printo-provisional-enthesitis-spondylitis-related-jia-criteria-performance-in-youth-classified-as-axial-disease-in-juvenile-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/printo-provisional-enthesitis-spondylitis-related-jia-criteria-performance-in-youth-classified-as-axial-disease-in-juvenile-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology